|Bid||24.44 x 800|
|Ask||0.00 x 800|
|Day's Range||62.98 - 62.98|
|52 Week Range||57.15 - 106.80|
|Beta (3Y Monthly)||0.91|
|PE Ratio (TTM)||28.50|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -22.81% and -8.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 20) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY )(announced ...
Biotech stocks went about a consolidation move last week, although a few swung wildly in either direction in reaction to some catalytic events. Aslan (NASDAQ: ASLN ) tumbled after its late-stage biliary ...
Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 45% and 39% respectively. Hedge funds' top 3 stock picks returned 34.4% this year and beat the S&P […]
Some Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) shareholders are probably rather concerned to see the share price fall...
Enanta Pharmaceuticals stock careened toward its lowest point in two years Thursday after its nonalcoholic steatohepatitis treatment didn't outperform a rival from Intercept Pharmaceuticals.
Enanta (ENTA) posts favorable top-line data from the phase IIa study on its pipeline candidate EDP-305 for treating NASH. Albeit the study meets its goals, the stock declines in after-hours trading.
The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 25.) Coherus Biosciences Inc (NASDAQ: CHRS ) The ...
Enanta Pharmaceuticals Inc said on Wednesday its drug to treat non-alcoholic steatohepatitis (NASH) met the main goal of reducing levels of elevated liver enzymes in a mid-stage study. NASH is a chronic liver disease characterized by excess fat, inflammation and cell damage in liver that can cause fibrosis or scarring of the organ, ultimately leading to cirrhosis or liver cancer. Successful treatments for NASH have remained elusive, but the market remains lucrative with some analysts having projected it could reach between $20 billion and $35 billion, as people with fatty diets increasingly develop the disease.
Anyone researching Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) might want to consider the historical volatility of the...
Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 371.43% and -4.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Enanta Pharmaceuticals (ENTA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Enanta Pharmaceuticals (ENTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
The thinly traded, small-cap biotech Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) announced results Friday from a midstage study. What Happened Enanta released top-line results from a Phase 2a study that ...
Jay Luly became the CEO of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) in 2003. This analysis aims first to contrast...
Enanta Pharmaceuticals Inc said on Friday its treatment for a highly contagious respiratory infection met the main goal of reducing virus levels in the body in a mid-stage study. The therapy, EDP-938, developed for treating respiratory syncytial virus (RSV) infection which currently has no available treatment, also helped improve symptoms in patients compared to placebo, the company said. RSV could lead to serious lung infections and even death in babies and the elderly who have a weaker immune system.